![semaglutide hepatic impairment child-pugh 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [4006] Hepatic Disease Drug Kinetics](https://www.thelancet.com/cms/10.1016/S2468-1253(23)00068-7/asset/fd53a887-7fc5-47e3-8cb1-2f290875bdb9/main.assets/gr3_lrg.jpg)
semaglutide hepatic impairment child-pugh 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [4006] Hepatic Disease Drug Kinetics
Description
Learn how MedLeanRx compares.
![semaglutide hepatic impairment child-pugh 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [4006] Hepatic Disease Drug Kinetics](https://cdn.psychopharmacologyinstitute.com/wp-content/uploads/2025/06/psychopharmacology-files/transcripts/%5B4006%5D+Hepatic+Disease+Drug+Kinetics+and+Child-Pugh+Classification/image1.jpeg)
Despite the development of several drugs for neuropathic pain management, their poor efficacy, tolerance, addiction potential, and side ...
![semaglutide hepatic impairment child-pugh 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [4006] Hepatic Disease Drug Kinetics](https://www.nejm.org/cms/10.1056/NEJMoa2413258/asset/94d9d294-b47a-4676-aadd-e77687e2b8b9/assets/images/large/nejmoa2413258_f2.jpg)
Over the years, one of the most interesting patterns Ive noticed has been...
![semaglutide hepatic impairment child-pugh 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [4006] Hepatic Disease Drug Kinetics](https://www.researchgate.net/publication/6345730/figure/tbl1/AS:667770215739405@1536220234286/Child-Pugh-classification-scores-for-patients-with-mild-moderate-or-severe-hepatic.png)
A weekly dose of semaglutide, the key ingredient in blockbuster medications Ozempic and Wegovy, helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three to six months in a small study.
![semaglutide hepatic impairment child-pugh 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [4006] Hepatic Disease Drug Kinetics](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-022-01140-3/MediaObjects/40262_2022_1140_Fig1_HTML.png)
